Myelofibrosis symptoms compromise health-related quality of life ( HRQoL ). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue Ruxolitinib due to loss of response or unacceptable toxicity.
Fedratinib ( Inrebic ) is an oral, selective JAK2 inhibitor for treatment of patients with intermediate-2 or high-risk myelofibrosis.
The single-arm, phase II JAKARTA2 trial assessed Fedratinib 400 mg/d ( starting dose ) in patients with myelofibrosis previously treated with Ruxolitinib.
Patient-reported changes in myelofibrosis symptom severity using the modified Myelofibrosis Symptom Assessment Form ( MFSAF ), and overall HRQoL and functional status using the EORTC QLQ-C30, were evaluated at each cycle.
Clinically meaningful changes from baseline HRQoL scores were based on effect sizes. Ninety patients were MFSAF-evaluable.
Myelofibrosis symptoms were mild-to-moderate at baseline.
Patients have shown statistically significant and clinically meaningful improvements in total symptom scores from baseline on the MFSAF at all post baseline visits through the end of cycle 6 ( EOC6 ).
Baseline global health status / QoL and functional domain scores on the EORTC QLQ-C30 were meaningfully worse than in the general population.
At EOC6, 44% of patients reported clinically meaningful improvements in global health status / QoL, and 30-53% of patients experienced clinically meaningful improvement in QLQ-C30 functional domains across post baseline timepoints.
Over 80% of ongoing patients perceived Fedratinib as beneficial on the Patient's Global Impression of Change questionnaire.
Fedratinib effects were consistent among prognostically relevant patient subgroups.
Patients with myelofibrosis previously treated with Ruxolitinib experienced clinically meaningful improvements in myelofibrosis symptom burden, overall HRQoL, and functional status in the first 6 months of Fedratinib treatment. ( Xagena )
Harrison Cn et al, Hemasphere 2021;5(5):e562. doi: 10.1097/HS9.0000000000000562